Anzeige
Mehr »
Login
Samstag, 20.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QJAY | ISIN: US19240Q2012 | Ticker-Symbol:
NASDAQ
19.04.24
21:59 Uhr
6,720 US-Dollar
+0,110
+1,66 %
1-Jahres-Chart
COGENT BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
COGENT BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur COGENT BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.04.Cogent Biosciences, Inc.: Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor80WALTHAM, Mass. and BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...
► Artikel lesen
22.03.Cogent Biosciences, Inc. - 8-K, Current Report2
26.02.Cogent Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans2
26.02.Cogent Biosciences, Inc. - 10-K, Annual Report-
26.02.Cogent Biosciences GAAP EPS of -$0.632
26.02.Cogent Biosciences, Inc. - 8-K, Current Report1
26.02.Cogent Biosciences, Inc.: Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results178• SUMMIT Part 2 registration-directed study of bezuclastinib in NonAdvSM patients initiated and actively enrolling at 40 sites globally; once-daily 100 mg selected as RP2D; topline results expected...
► Artikel lesen
22.02.Cogent Biosciences stock jumps on Phase 2 data for bezuclastinib3
22.02.Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis142Registration-enabling SUMMIT Part 2 initiated and actively enrolling at 40 sites globally; RP2D selected at 100 mg once-daily optimized formulation based on: 51% week 12 mean change in Total Symptom...
► Artikel lesen
14.02.HotStocks USA: Cogent Bio fast 45% im Plus4
14.02.Cogent Biosciences announces oversubscribed $225M private placement1
14.02.Cogent Biosciences, Inc. - 8-K, Current Report2
14.02.Cogent Biosciences, Inc.: Cogent Biosciences Announces Oversubscribed $225 Million Private Placement2
08.02.Citi starts Cogent Biosciences at buy, cites GI tumor drug potential1
05.02.Cogent Biosciences, Inc.: Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting1
09.01.Cogent Biosciences issues study updates on bezuclastinib, CGT48591
09.01.Cogent Biosciences, Inc.: Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics178Plan to initiate global, registration-directed SUMMIT Part 2 study of bezuclastinib in NonAdvSM patients during 1H 2024; present results from complete SUMMIT Part 1 at 2024 AAAAI annual conference...
► Artikel lesen
02.01.Cogent Biosciences, Inc.: Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference2
15.12.23Analyst Expectations for Cogent Biosciences' Future2
11.12.23Dow Surges 100 Points; Cogent Biosciences Shares Plunge3
Seite:  Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1